NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Cipla FY26 Revenue Hits Record INR 28,163 Cr; EBITDA Margins Contract to 21%
Cipla achieved its highest-ever annual revenue of INR 28,163 Cr in FY26, supported by double-digit growth in the India and North America segments. Despite the revenue growth, EBITDA margins contracted to 21.0% from 25.9% in FY25, and PAT declined to INR 3,879 Cr from INR 5,273 Cr. The company maintains a very strong balance sheet with a net cash position exceeding $1 billion (INR 11,140 Cr). Key strategic milestones include the approval of the first AB-rated gVentolin in the US and crossing the $400 Mn benchmark in North American quarterly revenue.
முக்கிய அம்சங்கள்
Annual revenue reached a record INR 28,163 Cr, with the One India business contributing 45% of total sales.FY26 EBITDA stood at INR 5,925 Cr with a margin of 21.0%, a decrease from the 25.9% margin reported in FY25.North America revenue grew 14% YoY in Q4 to $155 Mn, aided by the approval of gVentolin with CGT status.R&D investment for FY26 was INR 1,974 Cr, accounting for 7.0% of total revenue to support a complex generic pipeline.Net cash position strengthened to INR 11,140 Cr, providing significant capital for potential M&A and expansion.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin recovery trajectory and the commercial launch of gVentolin in the US. While revenue growth is robust, the year-on-year decline in profitability suggests cost pressures that need to be managed.
Cipla Q4 FY26 PAT Declines to ₹555 Cr; Board Recommends ₹13 Dividend
Cipla reported a weak Q4 FY26 with consolidated PAT falling significantly to ₹555 Cr from ₹1,222 Cr in the previous year. While the One-India business grew by a robust 15% YoY, the North America segment faced a 26% revenue decline during the quarter. Despite quarterly headwinds, the company achieved its highest-ever annual revenue of ₹28,163 Cr for the full year FY26. The company maintains a strong net cash position of ₹10,526 Cr and has proposed a final dividend of ₹13 per share.
முக்கிய அம்சங்கள்
Q4 FY26 PAT stood at ₹555 Cr, down from ₹1,222 Cr in Q4 FY25, with EBITDA margins contracting to 15.2%.One-India business grew 15% YoY in Q4, driven by double-digit growth across prescription, generics, and consumer health.North America revenue declined 26% YoY to ₹1,414 Cr in Q4, though it secured approval for the first AB-rated gVentolin.Full-year FY26 revenue reached a record ₹28,163 Cr with an annual EBITDA margin of 21.0%.Board recommended a final dividend of ₹13 per equity share (650% of face value).
👀 கவனிக்க வேண்டியவை
Investors should monitor the reasons behind the sharp margin contraction and North American revenue decline in Q4. While the India business remains a strong growth engine, the quarterly earnings miss may lead to short-term price volatility.
Cipla Receives USFDA Approval for First Generic Ventolin® HFA; Market Size ~$1.5 Billion
Cipla has received final USFDA approval for the first AB-rated generic version of Ventolin® HFA, targeting a U.S. albuterol market valued at approximately $1.5 billion. The product, Albuterol Sulfate Inhalation Aerosol, is scheduled for launch in the first half of FY 2026-27. This approval reinforces Cipla's leadership in the complex respiratory segment, where it already holds a significant market share. Manufacturing will be conducted at the company's dedicated inhalation facility in Fall River, Massachusetts, enhancing its domestic U.S. manufacturing footprint.
முக்கிய அம்சங்கள்
First AB-rated generic therapeutic equivalent of Ventolin® HFA approved by USFDATargets a total U.S. albuterol market opportunity of approximately $1.5 billionCommercial launch planned for H1 FY 2026-27 from the Fall River, Massachusetts facilityStrengthens Cipla's position as the 3rd largest player in the US Gx (Repulses + MDI) categoryVertically integrated inhalation platform used to ensure supply resilience and quality
👀 கவனிக்க வேண்டியவை
This approval is a significant milestone in Cipla's complex generics strategy and should be viewed as a long-term revenue driver for its U.S. business. Investors should monitor the ramp-up in market share and potential margin expansion following the H1 FY27 launch.
Cipla Receives 2 USFDA Observations for Goa Manufacturing Facility
The USFDA conducted a routine cGMP and Pre-Approval Inspection at Cipla's Verna, Goa facility from April 6 to April 17, 2026. The inspection concluded with the issuance of two observations in Form 483. Cipla has committed to addressing these observations comprehensively within the stipulated timeframe. While observations are a standard part of the regulatory process, the nature of these findings will determine future product approvals from this site.
முக்கிய அம்சங்கள்
USFDA inspection conducted at Verna, Goa facility from April 6 to April 17, 2026Company received 2 inspectional observations in Form 483Inspection covered routine cGMP and Pre-Approval Inspection (PAI) protocolsCipla committed to addressing observations within the stipulated time
👀 கவனிக்க வேண்டியவை
Monitor the company's response and the USFDA's final classification of the facility. Since there are only two observations, the risk of a Warning Letter is typically lower, but clarity on the severity is needed.
Cipla MD & CEO Umang Vohra to Step Down; Achin Gupta to Take Charge from April 2026
Cipla has announced a major leadership transition as Mr. Umang Vohra will conclude his 10-year tenure as Managing Director and Global CEO on March 31, 2026. Mr. Achin Gupta is set to take over the leadership role, supported by a newly designated senior management team including Saurabh Gambhir (Strategy & M&A) and Satyavan Manikani (Global Portfolio). The transition appears well-planned with a long lead time, ensuring stability in the company's strategic direction. This change marks the end of a significant era of growth and digital transformation under Vohra's leadership.
முக்கிய அம்சங்கள்
Mr. Umang Vohra to resign as MD & CEO effective April 1, 2026, after completing a 10-year tenure.Mr. Achin Gupta to be appointed as the new Managing Director and Global Chief Executive Officer.Two key executives, Saurabh Gambhir and Satyavan Manikani, elevated to Senior Management Personnel (SMP) status.The leadership change follows the completion of Vohra's current term and his decision not to seek re-appointment.Transition includes a focus on Strategy, M&A, and Global Portfolio management under the new CEO's direct reports.
👀 கவனிக்க வேண்டியவை
Investors should maintain a neutral stance as the transition is planned well in advance, minimizing immediate disruption. Monitor for any shifts in long-term strategy or capital allocation priorities once Achin Gupta officially takes charge in 2026.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Cipla Shareholders Approve Achin Gupta as MD & Global CEO with Over 99% Support
Cipla Limited has announced the successful passage of four key resolutions via postal ballot, including the appointment of Mr. Achin Gupta as Managing Director and Global CEO. The resolution for his appointment and remuneration received overwhelming support, with 99.86% and 99.63% votes in favor, respectively. While the re-appointment of Independent Director Mr. P.R. Ramesh was also approved with 83.01% total favor, it faced notable institutional resistance with 28.3% of institutional votes cast against it. Overall, the voting results confirm a stable transition in the company's top leadership.
முக்கிய அம்சங்கள்
Mr. Achin Gupta officially appointed as Managing Director and Global CEO with 99.86% shareholder approval.Remuneration package for the new MD & CEO cleared with 99.63% of votes in favor.Re-appointment of Independent Director P.R. Ramesh passed with 83.01% support, despite 110.58 million institutional votes against.Total voter participation was high at 80.58%, representing 650.9 million out of 807.78 million total shares.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the clear mandate given to the new CEO, which ensures management stability. Monitor for any strategic shifts in global operations under Mr. Achin Gupta's leadership.
Cipla Global Chief Scientific Officer Pradeep Bhadauria Resigns Effective March 31, 2026
Cipla Limited has announced the resignation of Mr. Pradeep Bhadauria from his role as Global Chief Scientific Officer and member of the Management Council. Mr. Bhadauria was an employee of Cipla USA Inc., a wholly owned subsidiary, and is leaving to pursue interests outside the organization. His tenure will officially conclude on March 31, 2026. This leadership change is noteworthy as the CSO role is critical for the company's R&D and product pipeline strategy.
முக்கிய அம்சங்கள்
Mr. Pradeep Bhadauria resigns as Global Chief Scientific Officer and Management Council member.The resignation is effective from the close of business on March 31, 2026.Mr. Bhadauria was an employee of Cipla USA Inc., a 100% subsidiary of the company.The departure is attributed to the executive pursuing interests outside of Cipla.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the announcement of a successor to ensure continuity in Cipla's complex generics and R&D pipeline. No immediate action is required as the transition period allows for a planned handover.
Cipla to Invest $100M in US Subsidiary and Merge Inzpera Healthsciences
Cipla's board has approved a significant investment of up to USD 100 million in its subsidiary Cipla (EU) Limited to fund the capital expenditure and working capital needs of InvaGen Pharmaceuticals in the US. Additionally, the company is merging its wholly-owned subsidiary Inzpera Healthsciences to streamline operations and leverage marketing strengths in the pediatric segment. Management changes were also announced, including the designation of P R Ramesh as Vice-Chairman effective April 1, 2026. These moves reflect a strategic focus on strengthening international operations and domestic efficiency.
முக்கிய அம்சங்கள்
Approved investment of up to USD 100 million in Cipla (EU) Limited for onward financial assistance to InvaGen Pharmaceuticals Inc.Scheme of Amalgamation approved for Inzpera Healthsciences Limited, which had a turnover of ₹26.74 crore in FY25.Mr. P R Ramesh designated as Vice-Chairman of the Company with effect from April 1, 2026.The merger of Inzpera will involve no cash consideration or share swap as it is a wholly-owned subsidiary.Investment in InvaGen is specifically targeted at capital expenditure, working capital, and general corporate purposes.
👀 கவனிக்க வேண்டியவை
Investors should view the $100M capital infusion as a positive sign of commitment to the US market growth. The merger of Inzpera is a routine but efficient consolidation that simplifies the corporate structure without any equity dilution.
Cipla USA Initiates Recall of Lanreotide Injection Leading to Temporary Supply Shortage
Cipla Limited's wholly owned subsidiary, Cipla USA Inc., has announced a recall of all unexpired batches of Lanreotide Injection. This decision was made following discussions with Pharmathen International S.A. and will result in a temporary lack of supply for this product in the market. The recall follows previous disclosures made by the company in January and February 2026, indicating an ongoing regulatory or quality issue. This development is expected to impact the company's US revenue from this specific product line in the near term.
முக்கிய அம்சங்கள்
Cipla USA Inc. to recall all unexpired batches of Lanreotide Injection from the market.The recall will lead to a temporary lack of supply for the injection in the US market.Decision follows discussions with partner Pharmathen International S.A. and previous updates in early 2026.The move is a disclosure under Regulation 30 of SEBI Listing Regulations.
👀 கவனிக்க வேண்டியவை
Investors should monitor the duration of the supply disruption and assess the potential impact on Cipla's US generic revenue. Watch for further management commentary on the specific reasons behind the recall and the timeline for market re-entry.
Cipla Enters 60:40 Joint Venture with Kemwell Biopharma for Global Biologics Expansion
Cipla Limited has entered into a 60:40 joint venture agreement with Kemwell Biopharma to develop, manufacture, and commercialize biologic products for global markets. The partnership leverages Kemwell's US FDA-certified Bangalore facility, which features a 5,000L bioreactor capacity and advanced protein therapeutic labs. Both partners will initially invest up to INR 10 crores in the new entity according to their shareholding ratio. This strategic move aims to strengthen Cipla's portfolio in the high-growth biosimilars and biologics segment.
முக்கிய அம்சங்கள்
Formation of a 60:40 joint venture between Cipla and Kemwell Biopharma for global biologicsInitial investment of up to INR 10 crores to be funded by partners in their respective JV ratiosAccess to Kemwell's US FDA-certified site in Bangalore with 5,000L bioreactor capacityFocus on end-to-end services including R&D, clinical programs, and commercial manufacturing of biosimilars
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic long-term positive as it enhances Cipla's capabilities in the complex biologics market. Monitor the JV's progress in product filings and regulatory approvals for global markets.
Cipla Incorporates Wholly-Owned Step-Down Subsidiary in Saudi Arabia
Cipla Limited has announced the incorporation of a new wholly-owned step-down subsidiary, Cipla Middle East Company, in the Kingdom of Saudi Arabia (KSA) effective March 1, 2026. The entity was established through Cipla (EU) Limited, UK, to facilitate manufacturing and distribution of pharmaceutical products within the region. This strategic move allows Cipla to hold marketing authorizations directly in KSA, strengthening its operational footprint in the Middle East. While initial turnover is not applicable, the 100% control indicates a long-term commitment to the Saudi pharmaceutical market.
முக்கிய அம்சங்கள்
Incorporation of 'Cipla Middle East Company' in Saudi Arabia effective March 1, 2026100% shareholding held by Cipla (EU) Limited, UK, making it a step-down subsidiaryEntity established for manufacturing, distribution, and holding marketing authorizations in KSAStrategic expansion into the Middle East pharmaceutical industry to enhance regional presence
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's progress in securing marketing authorizations in KSA, as this could drive long-term revenue growth in the Middle East. No immediate action is required as the financial impact will be realized over the coming years.
Cipla to Appoint Achin Gupta as MD & Global CEO for 5-Year Term Starting April 2026
Cipla Limited has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Achin Gupta as Managing Director and Global CEO for a five-year term effective April 1, 2026. The company is also seeking to re-appoint Mr. P.R. Ramesh as an Independent Director for a second five-year term starting July 1, 2026, which includes approval for his continuation beyond the age of 75. Shareholders can cast their votes via remote e-voting from February 24 to March 25, 2026, with results expected by March 30, 2026. This leadership transition marks a significant milestone for the company's long-term executive strategy.
முக்கிய அம்சங்கள்
Appointment of Achin Gupta as MD and Global CEO for a 5-year tenure from April 1, 2026, to March 31, 2031Re-appointment of P.R. Ramesh as Independent Director for 5 years from July 1, 2026, to June 30, 2031E-voting period scheduled between February 24, 2026, and March 25, 2026Cut-off date for shareholder voting eligibility set as February 20, 2026Final results of the postal ballot to be announced on or before March 30, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the leadership transition and any potential shifts in corporate strategy under the new CEO. Shareholders are encouraged to participate in the e-voting process to express their stance on the proposed appointments.
Cipla's Lanreotide Supply Partner Facility Classified as OAI by USFDA
Cipla Limited has been informed that the USFDA has classified the manufacturing facility of its supply partner, Pharmathen International S.A. in Greece, as Official Action Indicated (OAI). This facility is critical as it supplies Lanreotide Injection to Cipla's wholly owned subsidiary, Cipla USA Inc. An OAI classification indicates that the USFDA found significant compliance issues during its inspection in January 2026. This regulatory status could potentially lead to delays in product approvals or supply disruptions for this specific product line in the US market.
முக்கிய அம்சங்கள்
USFDA classifies Pharmathen International's Rodopi, Greece facility as Official Action Indicated (OAI).The facility is the primary supply partner for Cipla's Lanreotide Injection in the US market.The classification follows previous regulatory updates provided by the company on 7th and 14th January 2026.OAI status signifies that the USFDA may withhold product approvals or take further enforcement actions until remediation is complete.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the OAI status may impact the growth trajectory of Cipla's US specialty portfolio. Monitor management commentary regarding supply continuity and the timeline for remediation at the partner facility.
Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals, underwent a Pre-Approval Inspection (PAI) by the USFDA at its Hauppauge, New York facility from February 2 to February 9, 2026. Upon conclusion, the facility was issued 2 inspectional observations in Form 483. The company has committed to addressing these observations comprehensively within the stipulated timeframe. This inspection is critical as it is a Pre-Approval Inspection, which directly impacts the timeline for new product launches in the US market.
முக்கிய அம்சங்கள்
USFDA conducted a Pre-Approval Inspection (PAI) at the InvaGen facility in Hauppauge, New York.The inspection lasted 8 days, concluding on February 9, 2026.The facility received 2 observations in Form 483 following the audit.InvaGen Pharmaceuticals is a 100% wholly-owned subsidiary of Cipla Limited.Cipla intends to work closely with the USFDA to resolve the issues within the required timeline.
👀 கவனிக்க வேண்டியவை
Investors should monitor for further updates regarding the severity of the 2 observations, as successful resolution is necessary for upcoming product approvals. The low number of observations is generally manageable, but any escalation could delay US market expansion plans.
Cipla Faces GST Inspection at Maharashtra Facilities; Operations Unaffected
The Maharashtra Goods & Service Tax Department initiated inspection and search proceedings at Cipla's facilities and offices on February 5, 2026. The search, conducted under Section 67 of the MGST Act, focuses on tax payments, input tax credit claims, and refunds. While the proceedings are ongoing, the company has stated there is currently no financial impact or disruption to operations. Investors should monitor for any subsequent tax demands or penalties that might arise from this investigation.
முக்கிய அம்சங்கள்
GST Department, Maharashtra initiated search proceedings on February 5, 2026, at 12:30 PM.Investigation covers tax payments, input tax credit (ITC) claims, and refund processes.Action taken under Section 67(1) and 67(2) of the Maharashtra GST Act, 2017.Company reports no immediate financial impact or operational disruption due to the search.
👀 கவனிக்க வேண்டியவை
Monitor for further disclosures regarding any tax demand notices or penalties resulting from this inspection. No immediate sell-off is warranted as operations remain normal.
Cipla Q3 FY26: Revenue flat at Rs 7,074 Cr; EBITDA margin dips to 17.7% on Revlimid decline
Cipla reported flat year-on-year revenue of Rs 7,074 crores for Q3 FY26, primarily impacted by a sharp decline in generic Revlimid sales. The One-India business remained a bright spot with 10% growth, while the North America segment recorded $167 million in revenue. Profitability was pressured, with EBITDA margins falling to 17.7% and PAT at Rs 676 crores, which included a Rs 276 crore exceptional item for labor code changes. Management lowered the full-year FY26 EBITDA margin guidance to approximately 21% due to Lanreotide supply disruptions and increased R&D investments.
முக்கிய அம்சங்கள்
Revenue stood at Rs 7,074 crores (flat YoY) with EBITDA margin at 17.7% excluding other income.One-India business grew 10% YoY, with the respiratory segment crossing Rs 5,000 crores in IPM.Lanreotide supply is temporarily paused due to partner FDA issues, with resupply expected only in H1 FY27.R&D spending increased by 37.4% YoY to Rs 494 crores (7% of revenue) to support the future pipeline.Net cash position remains strong at Rs 10,229 crores despite dividend payments and acquisitions.
👀 கவனிக்க வேண்டியவை
Investors should be cautious due to the lowered margin guidance and Lanreotide supply issues, though the strong India growth and healthy cash balance provide long-term support. Monitor the progress of the Indore facility re-inspection and the transition to new leadership under Achin Gupta.
Cipla Announces New Leadership Team and KMP Changes Effective April 1, 2026
Cipla Limited has announced a transition in its Key Managerial Personnel (KMP) and authorized officers, effective from April 1, 2026. The Board has designated Mr. Achin Gupta as the Managing Director and Global CEO, while Mr. Ashish Adukia will serve as the Global CFO. These individuals, along with the Company Secretary and Global General Counsel, are authorized to determine the materiality of events for SEBI disclosures. The announcement follows a board meeting held on January 23, 2026, ensuring a planned leadership succession for the pharmaceutical giant.
முக்கிய அம்சங்கள்
Mr. Achin Gupta appointed as Managing Director and Global CEO effective April 1, 2026Mr. Ashish Adukia designated as the Global Chief Financial OfficerMs. Meera Vanjari (Global General Counsel) and Mr. Rajendra Chopra (CS) included in the authorized KMP listChanges are made under Regulation 30(5) of SEBI Listing Regulations for materiality disclosuresThe board meeting approving these changes concluded at 2:00 p.m. IST on January 23, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition for any changes in corporate strategy or capital allocation under the new leadership. No immediate action is required as the effective date is over two months away.
Cipla Q3 FY26: PAT Drops 57% YoY to ₹676 Cr; EBITDA Margins Contract to 17.7%
Cipla reported a challenging Q3 FY26 with flat revenue growth of 0.02% YoY at ₹7,074 crore. Profitability took a significant hit as EBITDA fell 36.9% to ₹1,255 crore and PAT plummeted 57% to ₹676 crore, impacted by rising material costs and exceptional items. While the India business showed resilience with 10% growth in branded prescriptions, the North America segment faces temporary headwinds due to a manufacturing pause for Lanreotide. The company maintains a very strong balance sheet with a net cash position of ₹10,229 crore.
முக்கிய அம்சங்கள்
Revenue remained nearly flat at ₹7,074 crore compared to ₹7,073 crore in Q3 FY25.EBITDA margins compressed significantly to 17.7% from 28.1% in the previous year's quarter.One India business contributed 49% of total revenue, with Respiratory therapy outperforming the market by 400+ bps.North America revenue stood at $167 million, with Albuterol maintaining a #1 market share of 22%.Net cash position strengthened to ₹10,229 crore, providing significant capital for strategic M&A like the Inzpera acquisition.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of EBITDA margins and the timeline for the re-supply of Lanreotide in the US market. While the India growth story and Pfizer partnership are positive, the sharp decline in quarterly profitability warrants a cautious outlook in the near term.
Cipla's Top-3 US Product Lanreotide Supply Paused Until H1 FY27 Following USFDA Observations
Cipla has confirmed a temporary production halt for Lanreotide Injection, a top-three product for its US subsidiary, following a USFDA inspection of its exclusive supplier, Pharmathen. The inspection at the Greece facility resulted in 9 observations, leading to a pause in manufacturing for remediation efforts. Re-supply to the US market is only expected to resume in the first half of FY 2026-27. This disruption is likely to impact Cipla's US revenue stream significantly until normal operations resume.
முக்கிய அம்சங்கள்
Lanreotide Injection is a top 3 product for Cipla USA, making it a critical revenue driver.Exclusive supplier Pharmathen received 9 USFDA Form 483 observations at its Greece plant.Supply is expected to remain limited until H1 FY 2026-27, indicating a disruption of over 12 months.The company is monitoring supply levels and is committed to remediation to restore stable supply.
👀 கவனிக்க வேண்டியவை
Investors should expect near-term pressure on US sales and margins; monitor management commentary for specific revenue loss estimates and remediation progress.
Cipla Clarifies on 9 USFDA Observations at Partner Pharmathen's Greece Facility
Cipla has confirmed that its supply partner, Pharmathen International S.A., received nine inspectional observations (Form 483) from the USFDA. The inspection occurred at Pharmathen's Rodopi, Greece facility between November 10 and November 21, 2025. This facility manufactures Lanreotide Injection for Cipla's US subsidiary, a key product in its portfolio. The company is currently evaluating the material impact of these observations on its US operations.
முக்கிய அம்சங்கள்
USFDA issued 9 inspectional observations in Form 483 to supply partner Pharmathen International S.A.The affected facility in Rodopi, Greece, manufactures Lanreotide Injection for Cipla USA Inc.Inspection was conducted over an 11-day period from November 10 to November 21, 2025.Cipla's stock price fell 4% following media reports of these observations prior to the official clarification.
👀 கவனிக்க வேண்டியவை
Investors should monitor the severity of the 9 observations as they could lead to supply disruptions for Lanreotide in the US market. Maintain a cautious stance until the company provides a detailed impact assessment or remediation timeline.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
